■颈动脉内中膜厚度(cIMT)的进展可以部分预测未来心血管事件的发生。这项网络荟萃分析比较了14种抗糖尿病药物(阿卡波糖,阿格列汀,艾塞那肽,格列本脲,格列美脲,Ipragragliflozin,二甲双胍,那格列奈,吡格列酮,罗格列酮,西格列汀,托福格利福津,曲格列酮,伏格列波糖)对cIMT的进展。
■PubMed,EMBASE,科克伦图书馆,和WebofScience在2024年3月1日之前搜索了所有用降糖药治疗cIMT的临床试验。评估治疗组与对照组之间cIMT变化的差异。
■筛选8395条引文后,包括25项研究(6675例患者)。结果表明,艾塞那肽在减缓cIMT进展方面具有最佳疗效,和艾塞那肽[MD=-0.13,95CI(-0.25,-0.01)],阿格列汀[MD=-0.08,95CI(-0.13,-0.02)]和二甲双胍[MD=-0.05,95CI(-0.09,-0.02)]比安慰剂更有效.
■艾塞那肽的长期治疗,阿格列汀,二甲双胍在减缓cIMT进展方面可能比其他降血糖药物更有效。
■https://www.crd.约克。AC.英国/PROSPERO/,标识符CRD42024519474。
UNASSIGNED: The progression of carotid intima-media thickness (cIMT) can partially predict the occurrence of future cardiovascular events. This network meta-analysis compared the effects of 14 antidiabetic drugs (acarbose, alogliptin, exenatide, glibenclamide, glimepiride, ipragliflozin, metformin, nateglinide, pioglitazone, rosiglitazone, sitagliptin, tofoglifozin, troglitazone, voglibose) on the progression of cIMT.
UNASSIGNED: PubMed, EMBASE, Cochrane Library, and Web of Science were searched to screen all clinical trials of treatment of cIMT with hypoglycemic agents before March 1, 2024. The differences in the changes in cIMT between the treatment group and control group were evaluated.
UNASSIGNED: After screening 8395 citations, 25 studies (6675 patients) were included. The results indicated that exenatide had the best efficacy in slowing down cIMT progress, and exenatide [MD=-0.13,95%CI (-0.25, -0.01)], alogliptin [MD=-0.08,95%CI (-0.13, -0.02)] and metformin [MD=-0.05, 95%CI (-0.09, -0.02)] are more effective than placebo.
UNASSIGNED: Long-term treatment of exenatide, alogliptin, and metformin may be more effective than other hypoglycemic drugs in slowing the progression of cIMT.
UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024519474.